Drug Trial Radar · NCT07636928
Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184
Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
9
Planned (sponsor's estimate)
Start
Jun 4, 2026
Primary completion
Aug 20, 2026
Study completion Aug 20, 2026
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jun 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the bioavailability, mass balance, pharmacokinetics, metabolism and excretion of radiolabeled (14C) VH4524184.
Conditions
- HIV Infections
Interventions
VH4524184Drug
One dose of VH4524184 is administered to participants at time zero on Day 1 (Period 1).
[14C]VH4524184 microdoseDrug
A radiolabelled microdose of \[14C\]VH4524184 is administered 2.5 hours after VH4524184 dose administration on Day 1 (Period1).
[14C]VH4524184Drug
One dose of radiolabelled \[14C\]VH4524184 is administered to participants at Day 15 (Period 2).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute bioavailability (F oral) of VH4524184 (Period 1)Time frame: Day 1 up to Day 14
- Amount of total radioactivity (TRA) excreted in urine (Ae urine) (Period 1)Time frame: Day 1 up to Day 14
- Amount of TRA excreted in urine (Ae urine) (Period 2)Time frame: Day 15 up to Day 43
- Amount of TRA excreted in feces (Ae feces) (Period 1)Time frame: Day 1 up to Day 14
- Amount of TRA excreted in feces (Ae feces) (Period 2)Time frame: Day 15 up to Day 43
- Amount of TRA excreted in vomitus (Ae vomit) (Period 1)Time frame: At Day 1
- Amount of TRA excreted in vomitus (Ae vomit) (Period 2)Time frame: At Day 15
- Total amount of TRA excreted (Ae total) (Period 1)Time frame: From Day 1 up to Day 14
- Total amount of TRA excreted (Ae total) (Period 2)Time frame: Day 15 up to Day 43
- Fraction of TRA excreted in urine (fe urine) (Period 1)Time frame: Day 1 up to Day 14
- Fraction of TRA excreted in urine (fe urine) (Period 2)Time frame: Day 15 up to Day 43
- Fraction of TRA excreted in feces (fe feces) (Period 1)Time frame: Day 1 up to Day 14
- Fraction of TRA excreted in feces (fe feces) (Period 2)Time frame: Day 15 up to Day 43
- Fraction of TRA excreted in vomitus (fe vomit) (Period 1)Time frame: At Day 1
- Fraction of TRA excreted in vomitus (fe vomit) (Period 2)Time frame: At Day 15
- Total fraction of TRA excreted (fe total) (Period 1)Time frame: Day 1 up to Day 14
- Total fraction of TRA excreted (fe total) (Period 2)Time frame: Day 15 up to Day 43
- Maximum concentration (Cmax) of VH4524184 in plasma (Period 1)Time frame: Day 1 to Day 14
- Maximum concentration (Cmax) of VH4524184 in plasma (Period 2)Time frame: Day 15 to Day 43
- Maximum concentration (Cmax) of [14C]VH4524184 in plasma (Period 1)Time frame: Day 1 to Day 14
- Maximum concentration (Cmax) of TRA in plasma (Period 1)Time frame: Day 1 to Day 14
- Maximum concentration (Cmax) of TRA in plasma (Period 2)Time frame: Day 15 to Day 43
- Cmax of TRA in whole blood (Period 1)Time frame: Day 1 to Day 14
- Cmax of TRA in whole blood (Period 2)Time frame: Day 15 to Day 43
- Time to maximum concentration (tmax) of VH4524184 in plasma (Period 1)Time frame: Day 1 to Day 14
- Time to maximum concentration (tmax) of VH4524184 in plasma (Period 2)Time frame: Day 15 to Day 43
- Time to maximum concentration (tmax) of [14C]VH4524184 in plasma (Period 1)Time frame: Day 1 to Day 14
- Time to maximum concentration (tmax) of TRA in plasma (Period 1)Time frame: Day 1 to Day 14
- Time to maximum concentration (tmax) of TRA in plasma (Period 2)Time frame: Day 15 to Day 43
- Time to maximum concentration (tmax) of TRA in whole blood (Period 1)Time frame: Day 1 to Day 14
- Time to maximum concentration (tmax) of TRA in whole blood (Period 2)Time frame: Day 15 to Day 43
- Area under the concentration-time curve from time zero to the last measured timepoint (AUC 0-t) of VH4524184 in plasma (Period 1)Time frame: Day 1 to Day 14
- Area under the concentration-time curve from time zero to the last measured timepoint (AUC 0-t) of VH4524184 in plasma (Period 2)Time frame: Day 15 to Day 43
- Area under the concentration-time curve from time zero to the last measured timepoint (AUC 0-t) of [14C]VH4524184 in plasma (Period 1)Time frame: Day 1 to Day 14
- Area under the concentration-time curve from time zero to the last measured timepoint (AUC 0-t) of TRA in plasma (Period 1)Time frame: Day 1 to Day 14
- Area under the concentration-time curve from time zero to the last measured timepoint (AUC 0-t) of TRA in plasma (Period 2)Time frame: Day 15 to Day 43
- Area under the concentration-time curve from time zero to the last measured timepoint (AUC 0-t) of TRA in whole blood (Period 1)Time frame: Day 1 to Day 14
- Area under the concentration-time curve from time zero to the last measured timepoint (AUC 0-t) of TRA in whole blood (Period 2)Time frame: Day 15 to Day 43
- Area under the concentration-time curve from time zero to infinity (AUC 0-inf) of VH4524184 in plasma (Period 1)Time frame: Day 1 to Day 14
- Area under the concentration-time curve from time zero to infinity (AUC 0-inf) of VH4524184 in plasma (Period 2)Time frame: Day 15 up to Day 43
- Area under the concentration-time curve from time zero to infinity (AUC 0-inf) of [14C]VH4524184 in plasma (Period 1)Time frame: Day 1 to Day 14
- Area under the concentration-time curve from time zero to infinity (AUC 0-inf) of TRA in plasma (Period 1)Time frame: Day 1 to Day 14
- Area under the concentration-time curve from time zero to infinity (AUC 0-inf) of TRA in plasma (Period 2)Time frame: Day 15 to 43
- Area under the concentration-time curve from time zero to infinity (AUC 0-inf) of TRA in whole blood (Period 1)Time frame: Day 1 to Day 14
- Area under the concentration-time curve from time zero to infinity (AUC 0-inf) of TRA in whole blood (Period 2)Time frame: Day 15 to Day 43
- Amount of VH4524184 excreted in urine (Ae urine) (Period 2)Time frame: Day 15 to Day 43
- Fraction of VH4524184 excreted in urine (fe urine) (Period 2)Time frame: Day 15 to Day 43
- Renal clearance of VH4524184 (CL R) (Period 2)Time frame: Day 15 to Day 43
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Groningen, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.